Literature DB >> 3975174

Familial factors affecting prostatic cancer risk and plasma sex-steroid levels.

A W Meikle, J A Smith, D W West.   

Abstract

Whether familial factors affect the frequency of prostatic cancer and the plasma content of sex-steroids was investigated. Brothers (n = 257) of probands (n = 150) diagnosed with prostatic cancer before age 62 years had a fourfold higher risk for developing the disease than men in the general population in the State of Utah and their brothers-in-law (n = 202). Familial factors markedly affected the plasma content of sex steroids (testosterone, dihydrotestosterone, the ratio of testosterone to DHT, sex-hormone binding globulin, and the free fraction of testosterone) in nonendocrinologically treated probands and their brothers and sons and in normal men in the general populations. Index cases and their brothers and sons had a significantly lower mean plasma testosterone content than controls of comparable age. Preliminary data suggest that the metabolic clearance rate of testosterone and the conversion ratio of testosterone to estradiol are relatively high in probands. The observations indicate that familial factors are potent risk factors for the development of prostatic cancer. They also suggest that plasma androgen values in families with prostatic cancer cluster in the lower range of normal and that plasma sex-steroid content is more similar in each brothers with or without prostatic cancer than among nonbrothers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3975174     DOI: 10.1002/pros.2990060202

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

1.  A genome screen of multiplex sibships with prostate cancer.

Authors:  B K Suarez; J Lin; J K Burmester; K W Broman; J L Weber; T K Banerjee; K A Goddard; J S Witte; R C Elston; W J Catalona
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

2.  Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis.

Authors:  Claire L Simpson; Cheryl D Cropp; Tiina Wahlfors; Asha George; Marypat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Teuvo Tammela; Johanna Schleutker; Joan E Bailey-Wilson
Journal:  Eur J Hum Genet       Date:  2012-09-05       Impact factor: 4.246

3.  Challenges with luteinizing hormone-releasing hormone agonists: flare and surge.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

4.  Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2003

5.  Mendelian inheritance of familial prostate cancer.

Authors:  B S Carter; T H Beaty; G D Steinberg; B Childs; P C Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

6.  Relationship between HLA-DR antigen and HLA-DRB1 alleles and prostate cancer in Japanese men.

Authors:  H Azuma; M Sada; T Tsuji; H Ueda; Y Katsuoka
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 7.  Hereditary aspects of prostate cancer.

Authors:  D L McLellan; R W Norman
Journal:  CMAJ       Date:  1995-10-01       Impact factor: 8.262

Review 8.  Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials.

Authors:  Landon W Trost; John P Mulhall
Journal:  J Sex Med       Date:  2016-05-18       Impact factor: 3.802

9.  Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations.

Authors:  K V Honn; A Aref; Y Q Chen; M L Cher; J D Crissman; J D Forman; X Gao; D Grignon; M Hussain; A T Porter; J E Pontes; I Powell; B Redman; W Sakr; R Severson; D G Tang; D P Wood
Journal:  Pathol Oncol Res       Date:  1996-03       Impact factor: 3.201

10.  Associations between coronary heart disease, obesity and histological prostate cancer.

Authors:  Konstantinos N Stamatiou; Alevizos G Alevizos; Konstantinos Mihas; Anargiros D Mariolis; Emmanuel Michalodimitrakis; Fragiskos Sofras
Journal:  Int Urol Nephrol       Date:  2006-09-28       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.